Anaemias and other Pesky Haematology Questions

Size: px
Start display at page:

Download "Anaemias and other Pesky Haematology Questions"

Transcription

1 Anaemias and other Pesky Haematology Questions

2 3 main topics How do I work out an anaemia.. That oh too common paraprotein patient. Those mildly raised lymphocyte count

3 GP discussed patient with me over weekend 83 yr female. Hb 103g/L. Stable level for previous 2 years MCV= 100. Plats/neuts = N Asymptomatic though previous recent TIAs

4 FIRST QUESTION IS THERE DECREASED PRODUCTION with LOW numbers of RETICULOCYTES OR INCREASED DESTRUCTION with INCREASE in RETICULOCYTES (as long as the necessary building blocks are present)

5 Increased retics= increase RBC destruction 1. Acute bleed with sufficient iron stores Or 2. Haemolytic anaemia Relatively rare Most will be referred for further work up

6 DECREASED PRODUCTION=Decreased reticulocytes 1. Lack of nutrients 2. Inflammatory process 3. Hormonal causes including lack of erythropoietin -i.e. renal impairment. Hypothyroid= relatively rare cause 4. Malproduction of haemopoietic cells i.e. myelodysplasia 5. Infiltration of bone marrow by a)fibrosis or b) malignancy

7 Our patient = Low reticulocytes- decreased production 1. Lack of nutrients? B12/folate =N (also ferritin= N) 2. Inflammatory process? CRP =N 3. Hormonal causes including lack of erythropoietin -i.e. renal impairment? Creatinine µmol/l. May be contributing a bit towards the Anaemia. Thyroid function normal.

8 DECREASED PRODUCTION=Decreased reticulocytes continued 4. Malproduction of haemopoietic cells i.e. myelodysplasia Most important test= BLOOD FILM Variation in size and shape of the red cells Hypo granulation of neutrophils May have reduction in neutrophils and platelets Q

9 5. Infiltration of bone marrow by a)fibrosis or b) malignancy BLOOD FILM very helpful Fibrosis associated with TEARDROPS and LEUKOERYTHROBLASTIC picture Needs bone marrow examination

10 5. Infiltration of bone marrow by b) malignancy Stable over last 2 years therefore unlikely to be aggressive malignancy Blood film again gave the clue Rouleaux Occurs when there is increased immunoglobulins from infection or paraprotein

11 Serum Electrophoresis showed IgM paraprotein of 25g/L If you had one test in this lady what would you do to maximise her management? 1. Bone marrow as she probably has myeloma 2. Serum viscosity as the IgM may increasing her risk of TIAs 3. A Serum Free Light Chain level 4. Bence Jones Protein

12

13 Ig M paraprotein in an otherwise asymptomatic patient with stable bloods IgM paraproteins MGUS rarely become myeloma usually low grade NHL MUST ask about night sweats/wt. loss/infections at EACH visit and tell them to report these MUST look for LN/L/S/abdominal masses at EACH visit

14 Low Grade NHL No definite benefit of early treatment ( at any age) of a LG NHL If very high IgM, once off plasma viscosity. Viscosity > 4 significant

15 Keeping to the theme of patients with paraproteins..

16 65 year woman steps awkwardly off a small stool Very significant thoracic pain X-ray showed some old looking thoracic fractures -?skiing accidents Prescribed slow release oxycodone by orthopaedic reg Still taking oxycodone 4 weeks later and significant pain

17 1 month later still taking oxycodone Bloods show normal full blood count, standard biochemistry and Total Ig G of 12 g/l (7-14) with a paraprotein present Normal IgM/A Kappa free light chain=86 mg/l ( ) Lambda free light chain = 63mg/L ( ) with a kappa/lambda ratio of 0.3mg/L ( )

18 What would you do? Which is most correct? 1. Explain to her that the serum free light chain results indicate myeloma 2. Explain to her it was inappropriate for her to be on oxycodone and in view of the normal IgG, she doesn t need to be followed up for a couple of years. 3. Undertake a urinary Bence Jones Protein as they are more reliable that serum free light chains. 4. Refer her to exclude a plasmacytoma

19 Int. Myeloma Working Group BJH, 2003; 121: Monoclonal Gammopathy of undetermined significance strict definition. 3% over the age of 50 yrs., 5% over the age of 70 yrs. No evidence of other B-cell disorders or amyloidosis M-protein < 30g/l and <10% plasma cells on BM No myeloma-related symptoms/organ damage

20 Rate of progression of MGUS Progression at 10 yrs. 9% 20 yrs. 20% 25 yrs. 30% 1% progression per year, for patients who have not died of other causes R L Spearing

21 But can we predict which will progress i.e. which need closer monitoring? Just based on the lab results, what would this mans chance be of progressing at 20 years 1. 5% % 3. 40% 4. 60% 5. 80%

22 How do you predict which patients will progress? 3 important factors help predict: 1. Type of paraprotein- If IgA more likely to progress than IgG (remember if a IgM paraprotein progresses - usually associated with a low grade lymphoma, not myeloma) 2. If serum free light chain RATIO is abnormal, more likely to progress 3. If high level of paraprotein i.e. >15g/L. However many labs don t quantify the paraprotein

23 Risk-Stratification Model to Predict Progression of MGUS to Myeloma Risk Group Low Risk Monoclonal protein <15 g/l, IgG type, normal FLC ratio Low-Intermediate Risk Any one factor abnormal High-Intermediate Risk Any two factors abnormal High-Risk (5% of group) All three factors abnormal Absolute Risk of Progression at 20 years 5% 21% 37% 58% Rajkumar Blood, 2005;106:

24 However this woman didn t have MGUS because she had bone pain Seen 7 months later, significant ongoing PAIN in thoracic region. Ig G now 18 g/l ( had been 12g/L, 7 months previously i.e. RATE of increase is important). Kappa serum free light chain=27 mg/l ( ) Lambda free light chain = 10 mg/l ( ) with a kappa/lambda ratio of 2.73 ( ) MRI showed multiple lytic lesions in the spine and the bone marrow 18% plasma cells i.e. myeloma

25 Recent move to treat myeloma earlier Previously international guidelines= needed raised calcium /renal impairment/anaemia/bone pain (CRAB) before treating Now - low dose CTs performed on MGUS with high risk features Indication to treat = 2 lesions on MRI/CT scan; SFLC ration of >100 plasma cell >60% even without end organ damage

26 Lessons from this case Pain out of proportion to the injury Bence Jones protein is an obsolete test Ratio of the 2 light chains is what to look as both will go up in infection Rate of rise of the paraprotein or SFLC is important as well as total level

27 A sad case 51 yr. old woman screening for a weight loss trial. Kappa paraprotein -low total IgG of 7g/L and an initially N SFLC ratio, though by the next year had become weakly positive mg/L ( ) Asymptomatic 5% risk of progressing to MM, lymphoma or other B Cell neoplasm at 20 years However, SFLC ratio and Ig level then stable for next 7 years and so FU extended to 6-12 monthly

28 SFCL Ratio Dec 2013 increased from 3.39 to 4.96 ( ) Ig G unchanged Letter from locum is that increase significant? I am quite happy with her present IgG level and her SFLC ratio No absolute cut off for when a serum free light chain may be of significance but usually it is at least 100. Thank you for continuing to monitor her with 6 to 12 monthly serum free light chains, immunoglobulins, calcium, albumin, creatinine and full blood count and questions about weight loss, night sweats and bone pain. Examination should include looking for palpable liver spleen and lymph nodes.

29 What I didn t say was the RATE of rise = Important Oct 2014 SCLF =20.2 up from 4.9 ten months earlier (N= ) Jan 2015 developed pain visited new locum x9 times. Referred to musculoskeletal specialist in July who repeated the SFLC ratio now Bone marrow 90% plasma cells. Pain very difficult to control.

30 Myeloma update Newer drugs such as S/C weekly bortezomib/weekly 40mg dexamethasone plus cyclophosphamide followed by stem cell transplant for <70year olds = median survival of 7-9 years Bortezomib/dexa/cyclo without transplant reasonably tolerated up into 70s, some 80s. Dose of weekly dexa 20mg/wk. NB: Significant bone pain even with a low level paraprotein can be a plasmacytoma RATE of RISE of paraprotein/sflc important - Not absolute figure.

31 Chronic lymphocytosis GP referral- Written advice only Semi-urgent - 24-Jul :26 chronic lymphocytosis.?monitor yearly or needs to be seen blood test shows lymphocytosis recommend marker studies no wt. loss no recurrent infections no night sweats. wt. 107 no lymphadenopathy neck axilla groin abdo snt. no hepatosplenomegaly. P lymphocyte marker studies.

32 Mild Lymphocytosis- When should one recheck it? Nothing hard and fast needs to be put into clinical context?viral symptoms/wt. loss/recurrent infections/night sweats/lymphadenopathy neck axilla groin/hepatosplenomegaly This man had only had 1 previous blood test - Lymphocytes had been 6 x10 9 /L in 2013.

33 Request a film on the FU film If no symptoms suggest do FU film at 6 weeks but instruct to return sooner if symptoms. Film may show large activated lymphocytes as per a viral infection May show smear cells occur in Chronic Lymphocytic Leukaemia but are non-specific The lab may see other significant abnormalities

34 What do you not want to miss? Common things are common most mild lymphocytosis=either viral or early CLL However diagnoses not to miss e.g. a Mantle Cell Lymphoma Therefore need surface markers (SM) -Can ask for surface markers please if lymphocytes still raised Costs around $400 so do it once only do NOT need repeating

35 Frequent result- Clonal B-Cell Lymphocytosis The phenotype is that of Chronic Lymphocytic Leukaemia. However, the clone of abnormal cells is less than 5x 10 9 /L, so unless there is a palpable spleen, or lymph nodes, it doesn t meet the full clinical criteria of Chronic Lymphocytic Leukaemia and would fall in to the category of Clonal B-Cell Lymphocytosis. Unless there are clinical features to indicate otherwise, only infrequent follow up is indicated. (Monoclonal B-Cell Lymphocytosis. Rawstron et al, NEJM 2008;359;6). See also Health Pathways

36 Clonal lymphocytosis of unknown significance (CLUS) Low level, subclinical "disease" <5 x /l with classical Chronic Lymphocytic Leukaemia markers on immunophenotyping Present in 3.5% of normal adults - up to 8% of individuals over the age of 70 13% have 1st degree relatives with CLL Analogous to MGUS- unclear as to what % will progress: Appears to lead to mild disease

37 Again clinical history and examination all important MUST ask about night sweats/wt. loss/infections at EACH visit and tell them to report these MUST look for LN/L/S at EACH visit If no red flags, yearly or even 2 yearly follow up is appropriate No need to repeat SM when the increase in lymphocytes makes the diagnosis officially CLL

38 CLL In CLL, the height of the white count unimportant Indication to refer: Hb or platelet count dropping out of the normal range Development of splenomegaly Significant LNs

39 Summary of take home points Have a simple schema for anaemais Importance of reticulocyte count and blood film in sorting out anaemias If a patient has a even a low level of paraprotein with bone pain, think of plasmacytoma The RATE of change for immunoglobulins/sflc is important Bence Jones Protein = obsolete In a patient with a CLUS you don t need to repeat the surface markers when the count increases

40

Southern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance)

Southern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance) Southern Derbyshire Shared Care Pathology Guidelines MGUS (Monoclonal Gammopathy of Undetermined Significance) Purpose of guideline This guideline provides information about the risk stratification of

More information

Rory McCulloch. Specialty Trainee Haematology Royal Devon & Exeter Hospital

Rory McCulloch. Specialty Trainee Haematology Royal Devon & Exeter Hospital Rory McCulloch Specialty Trainee Haematology Royal Devon & Exeter Hospital Anaemia 1 Haematological disorders Anaemia 2 Non-haematological disorders Substrates: Iron, folate, vitamin B12 Red cell mass

More information

Michael Joffe ST6 Haematology SpR

Michael Joffe ST6 Haematology SpR Michael Joffe ST6 Haematology SpR Mrs SB 71 year old female on AMU Telephone referral to haematology by medicine with Hb 102 MCV 89, normal B12, Folate, Ferritin. PMH DM General decline over several weeks

More information

GP Referral Guidelines. for. South Wales Cancer Network. Document Control Sheet. Specialty/Project Haematological Site Specific Group

GP Referral Guidelines. for. South Wales Cancer Network. Document Control Sheet. Specialty/Project Haematological Site Specific Group GP Referral Guidelines for South Wales Cancer Network Document Control Sheet Organisation South Wales Cancer Network Specialty/Project Haematological Site Specific Group Document Title GP Referral Guidelines

More information

Hematology 101. Rachid Baz, M.D. 5/16/2014

Hematology 101. Rachid Baz, M.D. 5/16/2014 Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More

More information

Plasma cell myeloma (multiple myeloma)

Plasma cell myeloma (multiple myeloma) Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells

More information

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016 + Disclosures Advisory Boards: AMGEN, Lundbeck, NOVARTIS + Subtypes of Plasma Cell Disorders Increased Plasma

More information

Haematological Cancer Suspected (Adults & Children)

Haematological Cancer Suspected (Adults & Children) Haematological Cancer Suspected (Adults & Children) Link to NICE guidelines: https://www.nice.org.uk/guidance/ng47 Patient of any age presents with symptoms of possible haematological cancer If 60 years

More information

GP CME. James Liang Consultant Haematologist. Created by: Date:

GP CME. James Liang Consultant Haematologist. Created by: Date: GP CME James Liang Consultant Haematologist Date: Created by: Scenario 52 year old European male Fit and well Brother recently diagnosed with diabetes PMHx Nil Social Hx Ex-smoker stopped 5 years ago (20

More information

Western Health Specialist Clinics Access & Referral Guidelines

Western Health Specialist Clinics Access & Referral Guidelines Haematology Specialist Clinics at Western Health: Western Health runs MBS funded Specialist Clinics on a Wednesday and Thursday afternoon at its Sunshine Hospital site for patients who require assessment

More information

Blood Cancers in the Community

Blood Cancers in the Community Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James

More information

Candidates must answer ALL questions

Candidates must answer ALL questions Time allowed: Three hours. Part 1 examination Haematology: First paper Tuesday 22 March 2016 Candidates must answer ALL questions Question 1: General Haematology A 16 year old non-european is referred

More information

2013 AAIM Pathology Workshop

2013 AAIM Pathology Workshop 2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone

More information

TYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA

TYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA TYPE 1 GAUCHER DISEASE PRESENTING AS PERSISTENT THROMBOCYTOPENIA, ASSOCIATED FACTOR XI DEFICIENCY & EMERGENT MYELOMA Trish Hyland, Medical Scientist, Department of Haematology, Cork University Hospital

More information

Criteria for Disease Assessment Joan Bladé

Criteria for Disease Assessment Joan Bladé Criteria for Disease Assessment Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona COMy Meeting, París, May 4th, 2018 Response Evaluation EBMT, 1998 - CR and

More information

FBC interpretation. Dr. Gergely Varga

FBC interpretation. Dr. Gergely Varga FBC interpretation Dr. Gergely Varga #1 71 Y/O female, c/o weakness Test Undertaken : FBC (FBC) Sample Type: Whole Blood [ - 26.09.11 14:59] Hb 7.3 g/dl* 12.0-15.5 RBC 3.5 10^12/l * 3.80-5.60 Hct 0.24

More information

Lec-14 د.خالد نافع. Medicine. Multiple Myeloma

Lec-14 د.خالد نافع. Medicine. Multiple Myeloma Fifth stage Lec-14 د.خالد نافع Medicine 24/4/2016 Multiple Myeloma Plasma cell myeloma Variants Non - secretory myeloma Indolent myeloma Smouldering myeloma Plasma cell leukaemia Plasmacytoma - Solitary

More information

Multiple Myeloma 101: Understanding Your Labs

Multiple Myeloma 101: Understanding Your Labs Multiple Myeloma 101: Understanding Your Labs Tim Wassenaar MD MS Hematologist, Director of Clinical Trials UW Cancer Center at ProHealth Care None Disclosures Outline Define hematopoiesis WBCs, RBCs,

More information

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar Serum free light chain (SFLC) assays Dr Sarah Sasson SydPath Registrar Introduction to SFLC Plasma cell dyscrasias such as monoclonal gammopathy of uncertain significance (MGUS) smouldering/asymptomatic

More information

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification

More information

Common Haematological Problems in Primary Care

Common Haematological Problems in Primary Care 23 rd March 2019 GP Hot Topics In Primary Care Common Haematological Problems in Primary Care Dr Samar Kulkarni Consultant Haematologist-Oncologist and The Christie Private Care Manchester, UK. Haematology?

More information

Case #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute

Case #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute Case #1 Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute Patient History Part I 76 year-old man 1997 diagnosed with MGUS (biclonal) during evaluation of (self-limited) anemia.

More information

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology

More information

Mr Matthew Eby. Dr Humphrey Pullon

Mr Matthew Eby. Dr Humphrey Pullon Dr Humphrey Pullon Haematologist Hamilton Mr Matthew Eby Senior Support Services Coordinator Leukaemia & Blood Cancer Foundation New Zealand Hamilton 16:30-17:25 WS #64: Managing Haemopoetic Disease in

More information

The ABCs of Waldenström s Macroglobulinemia (WM)

The ABCs of Waldenström s Macroglobulinemia (WM) The ABCs of Waldenström s Macroglobulinemia (WM) Jeffrey V. Matous MD Colorado Blood Cancer Institute IWMF Ed Forum May 2017 Objectives Describe the roots underneath WM Review incidence, possible risk

More information

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD Department of Oncology & Hematology AZ Nikolaas Iridium Kanker Netwerk Introduction Multiple myeloma = Kahler s disease Dr.

More information

King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology

King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology 1 Version control: There are two controlled versions of this document, one for GSTT and one for KCH. While

More information

If unqualified, Complete remission is considered to be Haematological complete remission

If unqualified, Complete remission is considered to be Haematological complete remission Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous

More information

If unqualified, Complete remission is considered to be Haematological complete remission

If unqualified, Complete remission is considered to be Haematological complete remission Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous

More information

King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology

King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology King s Health Partners Haematology Institute and Network GP Referral Guide, Adult Haematology For two week wait pathway, please continue to use existing documentation/pathways. Telephone advice and guidance

More information

Morphology Case Study. Presented by Niamh O Donnell, BSc, MSc. Medical Scientist Haematology Laboratory Cork University Hospital

Morphology Case Study. Presented by Niamh O Donnell, BSc, MSc. Medical Scientist Haematology Laboratory Cork University Hospital Morphology Case Study Presented by Niamh O Donnell, BSc, MSc. Medical Scientist Haematology Laboratory Cork University Hospital 41 year old male presented to GP for routine check-up in May 2011. FBC Results:

More information

Hematology Case Conference 8/5/03

Hematology Case Conference 8/5/03 Hematology Case Conference 8/5/03 Bone Marrow Case Patient: Emmxxx Lylexxx 74 year old AA female S/P craniotomy for SDH. Pt has Hx of HTN, DM, Crohn s disease, (R) nephrectomy. Bone marrow for abnormal

More information

Suspecting Tumors, or Could it be cancer?

Suspecting Tumors, or Could it be cancer? Suspecting Tumors, or Could it be cancer? Donna E. Reece, M.D. Princess Margaret Cancer Centre University Health Network Toronto, ON CANADA 07 February 2018 Background Low back pain is common However,

More information

TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers

TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers TESTS AND INVESTIGATIONS FOR MULTIPLE MYELOMA A guide for patients and caregivers Developed by the Myeloma Special Practice Network (M-SPN) of the Haematology Society of Australia and New Zealand (HSANZ)

More information

The patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:

The patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was: Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-

More information

Smoldering Multiple Myeloma. A Case Study

Smoldering Multiple Myeloma. A Case Study Smoldering Multiple Myeloma A Case Study Case Presentation 53-Year-Old Male Patient presented for a routine exam No prior history of disease or family history of fhematologic disorders d or malignancies,

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016 MYELOMA Quantitative Markers-Myeloma Assessment Quantitative markers are biochemicals that are recorded in tests on body fluids such as serum and urine. Applicable Disease Sites The myeloma disease site

More information

Osteosclerotic Myeloma (POEMS Syndrome)

Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Synonyms Crow-Fukase syndrome Multicentric Castleman disease Takatsuki syndrome Acronym coined by Bardwick POEMS Scheinker,

More information

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015

Multiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015 Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the

More information

Problem Based Learning

Problem Based Learning Problem Based Learning 2 Dania Qarqash&OmaymaHassanin Enas Ajarma Dr.Hikmat Abdel-Razeq Clinical hematology is divided into four subjects : 1- Benign hematology Anemia Benign WBC disorders Bone marrow

More information

Haematology dilemma s to refer or not to refer?

Haematology dilemma s to refer or not to refer? Haematology dilemma s to refer or not to refer? NWL Pathology GP Study Day Dr Fatts Chowdhury Consultant Haematologist in Transfusion Medicine NHS Blood and Transplant Senior Honorary Clinical Lecturer

More information

Bortezomib (Velcade)

Bortezomib (Velcade) Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)

More information

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona Málaga, 16 de noviembre

More information

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune

More information

Complete Blood Count in Primary Care

Complete Blood Count in Primary Care QUIZ FEEDBACK Complete Blood Count in Primary Care bpac nz better medicine GP Review Panel: Dr Janine Bailey, Motueka Dr Susie Lawless, Dunedin Dr Randall Sturm, Auckland Dr Neil Whittaker, Nelson Specialist

More information

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q: If polycythemia ruba vera (PRV) or essential thrombocythemia (ET) is diagnosed by peripheral smear,

More information

Leukocytosis - Some Learning Points

Leukocytosis - Some Learning Points Leukocytosis - Some Learning Points Koh Liang Piu Department of Hematology-Oncology National University Cancer Institute National University Health System Objectives of this talk: 1. To provide some useful

More information

NICE guideline on Suspected cancer: recognition and referral (2015) Education package for GPs and Nurse Practitioners Case scenarios

NICE guideline on Suspected cancer: recognition and referral (2015) Education package for GPs and Nurse Practitioners Case scenarios NICE guideline on Suspected cancer: recognition and referral (2015) Education package for GPs and Nurse Practitioners Case scenarios How to use the case scenarios The case scenarios can be used in a training

More information

Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL) Page 1 of 10 PATIENT EDUCATION Chronic Lymphocytic Leukemia (CLL) Introduction Chronic lymphocytic leukemia (CLL) is a type of cancer of the lymphocytes (a kind of white blood cell). It is also referred

More information

FBC CASES Vernon Louw Clinical Haematology 2010

FBC CASES Vernon Louw Clinical Haematology 2010 FBC CASES Vernon Louw Clinical Haematology 2010 FOR EACH OF THE FOLLOWING PATIENTS, SELECT THE MOST LIKELY FINDING FROM THE ANALYSIS OF THE PERIPHERAL BLOOD. A patient with infectious mononucleosis. A

More information

Management of Multiple Myeloma

Management of Multiple Myeloma Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.

More information

POEMS syndrome. This Infosheet explains what POEMS syndrome is, how it is diagnosed and how it is treated and managed.

POEMS syndrome. This Infosheet explains what POEMS syndrome is, how it is diagnosed and how it is treated and managed. POEMS syndrome This Infosheet explains what POEMS syndrome is, how it is diagnosed and how it is treated and managed. What is POEMS syndrome? POEMS syndrome is a rare type of plasma cell disorder that

More information

Smoldering Myeloma: Leave them alone!

Smoldering Myeloma: Leave them alone! Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002

More information

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose

MYE FORMS REVEALED RESPONSE CODES OBJECTIVES. Stringent Complete Response (scr) Complete Response (CR) I have no conflicts of interest to disclose I have no conflicts of interest to disclose MYE FORMS REVEALED Janet Brunner, PA-C CIBMTR MKE New10_1.ppt OBJECTIVES 1) Be able to describe the criteria required for each myeloma response code 2) Be able

More information

Forms Revision: Myeloma Changes

Forms Revision: Myeloma Changes Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.

More information

Cytopaenias in HIV. Dr Maresce Bizaare Specialist Physician Clinical Haematology Fellow IALCH

Cytopaenias in HIV. Dr Maresce Bizaare Specialist Physician Clinical Haematology Fellow IALCH Cytopaenias in HIV Dr Maresce Bizaare Specialist Physician Clinical Haematology Fellow IALCH Introduction Cytopaenias in HIV are common Anaemias multifactorial causes Thrombocytopaenias may be the first

More information

Multiple Myeloma Early Detection, Diagnosis, and Staging

Multiple Myeloma Early Detection, Diagnosis, and Staging Multiple Myeloma Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be

More information

Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain

Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option

More information

Blood Cancer: Chronic Myelogenous Leukaemia

Blood Cancer: Chronic Myelogenous Leukaemia Published on: 30 May 2017 Blood Cancer: Chronic Myelogenous Leukaemia What Is Cancer? The body is made up of cells that grow and die in a controlled way. Sometimes, cells keep dividing and growing without

More information

Part 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks.

Part 1 examination. Haematology: First paper. Tuesday 20 March Candidates must answer all questions. Each question is worth a total of 25 marks. Part 1 examination Haematology: First paper Tuesday 20 March 2018 Candidates must answer all questions. Each question is worth a total of 25 marks. Time allowed: 3 hours Question 1: General Haematology

More information

Monoclonal Gammopathy with Systemic Amyloidosis: An Evaluation of Diagnostic Elements

Monoclonal Gammopathy with Systemic Amyloidosis: An Evaluation of Diagnostic Elements : 51-55 Monoclonal Gammopathy with Systemic Amyloidosis: An Evaluation of Diagnostic Elements 1 C. T Subashini*, 1 E. George & 2 U Nor Aini 1 Department of Pathology, Faculty of Medicine and Health Sciences,

More information

GP Education Haematology laboratory abnormalities- when to refer? Priyanka Mehta Consultant Haematologist UH Bristol NHS Trust

GP Education Haematology laboratory abnormalities- when to refer? Priyanka Mehta Consultant Haematologist UH Bristol NHS Trust GP Education Haematology laboratory abnormalities- when to refer? Priyanka Mehta Consultant Haematologist UH Bristol NHS Trust Topics for discussion Abnormal FBCs Lymphocytosis high and low platelets cytopenias

More information

Hematology: Challenging Cases with Your Participation COPYRIGHT

Hematology: Challenging Cases with Your Participation COPYRIGHT Hematology: Challenging Cases with Your Participation Reed E. Drews, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Question 1 Question 1 64-year-old man is evaluated during

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below

More information

Borderline cytopenias. Dr Taku Sugai Consultant Haematologist

Borderline cytopenias. Dr Taku Sugai Consultant Haematologist Borderline cytopenias Dr Taku Sugai Consultant Haematologist Borderline cytopenias Neutropenia Thrombocytopenia Anaemia with normal haematinics Two recent cases of cytopenias Neutropenia ANC of more than

More information

Management Update: Multiple Myeloma. Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College

Management Update: Multiple Myeloma. Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College Management Update: Multiple Myeloma Presented by Prof. Dr. Khan Abul Kalam Azad Professor of Medicine Dhaka Medical College Introduction Multiple myeloma - clonal plasma cell neoplasm Monoclonal antibody

More information

Multiple myeloma: from diagnosis to treatment

Multiple myeloma: from diagnosis to treatment Diagnostic challenges Renee Eslick Dipti Talaulikar Multiple : from diagnosis to treatment Background Multiple is characterised by the proliferation of malignant plasma cells within the bone marrow, which

More information

HEFT Pathology Guideline. GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia

HEFT Pathology Guideline. GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia HEFT Pathology Guideline GP Investigation and Referral Pathways for leucocyte, platelet disturbances and polycythaemia Produced by: Dr Charalampos Kartsios (Consultant Haematologist) and Muhammad Javed

More information

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance S. Vincent

More information

IBRUTINIB (IMBRUVICA ) for Chronic Lymphocytic Leukaemia. and Mantel Cell Lymphoma

IBRUTINIB (IMBRUVICA ) for Chronic Lymphocytic Leukaemia. and Mantel Cell Lymphoma DRUG ADMINISTRATION SCHEDULE Indication Cycle Length Drug Daily Dose Route Schedule Chronic Lymphocytic Leukaemia Continuous Ibrutinib 420mg (three capsules) Oral ONCE daily Mantel Cell Lymphoma Continuous

More information

Alister Jones Patient Blood Management Practitioner NHS Blood and Transplant

Alister Jones Patient Blood Management Practitioner NHS Blood and Transplant Alister Jones Patient Blood Management Practitioner NHS Blood and Transplant All medical RCC transfusions (but only 1 in 3 haematology or oncology cases) in 3 x one week periods Medical specialties include:

More information

Interpreting Blood Tests Part 1. Dr Andrew Smith

Interpreting Blood Tests Part 1. Dr Andrew Smith Interpreting Blood Tests Part 1 Dr Andrew Smith Outline Part 1 (This Week) Introduction Which Tube!?! FBCs U+Es Part 2 (Next Week): More Electrolytes LFTs Clotting Extras Introduction Bloods are a core

More information

CLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler

CLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer

More information

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Case Workshop of Society for Hematopathology and European Association for Haematopathology Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below

More information

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Plasma cell dyscrasias Plasma

More information

Haematology for GP's

Haematology for GP's Haematology for GP's Dr Christina Zouvelou Consultant Haematologist SOUTHEND UNIVERSITY HOSPITALS NHS FT SPIRE WELLESLEY HOSPITAL Time to Learn, 03/07/2018 Anaemia Careful history (duration, symptoms,

More information

Citation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.

Citation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n. University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

More information

WHAT IS YOUR DIAGNOSIS?

WHAT IS YOUR DIAGNOSIS? WHAT IS YOUR DIAGNOSIS? A 12 year old, female neutered domestic shorthaired cat was presented to the R(D)SVS Feline Clinic with a 6 week history of polydipsia and polyuria, which was not quantified. The

More information

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e Pathology #07 Mature B-Cell Neoplasm Hussein Al-Sa di Dr. Sohaib Al-Khatib 0 P a g e Thursday 18/2/2016 Our lecture today (with the next 2 lectures) will be about lymphoid tumors This is a little bit long

More information

Myeloma. A guide for patients and families leukaemia.org.au

Myeloma. A guide for patients and families leukaemia.org.au Myeloma A guide for patients and families 1800 620 420 leukaemia.org.au Contents Acknowledgments 4 Introduction 5 The Leukaemia Foundation 6 Blood cancers 10 What is myeloma? 16 Who gets myeloma? 20 How

More information

Laboratory Examination

Laboratory Examination Todd Zimmerman, M.D. 64 year old African American male presents to establish care with PCG. Meds: Norvasc 5 mg daily PMHx: HTN x 20 years, poorly controlled SHx: No tobacco, illicit; rare EtOH ROS: Negative

More information

Dr Prashant Tembhare

Dr Prashant Tembhare Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers

More information

PLASMA CELL NEOPLASIA. Michael Miller, MD & Ajaz Shawl, MD

PLASMA CELL NEOPLASIA. Michael Miller, MD & Ajaz Shawl, MD PLASMA CELL NEOPLASIA Michael Miller, MD & Ajaz Shawl, MD Plasma Cell Neoplasia Board Questions Case Presentation Introduction Epidemiology Presentation Diagnosis Laboratory Tests Imaging Differentials

More information

Investigation and Management of Chronic Lymphocytic Leukemia. James Johnston

Investigation and Management of Chronic Lymphocytic Leukemia. James Johnston Investigation and Management of Chronic Lymphocytic Leukemia James Johnston Site Specific Clinics CLL Clinic (787-4454) Erin Elphee BN James Johnston Rajat Kumar Matt Seftel (transplant) Myeloma Clinic

More information

The Lymphomas. An overview..

The Lymphomas. An overview.. The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded

More information

2016: Plasma Cell Disorders Pre-HCT Data

2016: Plasma Cell Disorders Pre-HCT Data 2016: Plasma Cell Disorders Pre-HCT Data Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Date of HCT for which this form is being completed: / / YYYY MM DD HCT type (check

More information

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail

More information

Plasma Cell Disorders (PCD) Pre-HCT Data

Plasma Cell Disorders (PCD) Pre-HCT Data Plasma Cell Disorders (PCD) Pre-HCT Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: HCT type: (check

More information

Diseases Of The Blood

Diseases Of The Blood Diseases Of The Blood DR. Associate Professor Of Pathology Faculty Of Medicine Ain Shams University Red Blood Cells and Anemia RBC=4-6 million/mm 2 Hb=12-18 g/dl Oxygen Carrying Molecule Hemoglobin Tetramer:

More information

Dr Kirsten Herbert. Dr Melita Kenealy. MBBS(Hons) FRCPA FRACP. Common Blood Tests

Dr Kirsten Herbert. Dr Melita Kenealy. MBBS(Hons) FRCPA FRACP. Common Blood Tests Common Blood Tests Your Haematologist may order numerous blood and urine tests to help diagse or manage your condition. Listed below are some of the more common tests that can be ordered in a haematology

More information

Anemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017

Anemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017 Anemia A case-based approach David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017 Recognizing trends Learning Objectives MCV, RDW, Ferritin, LDH, Reticulocytes Managing complex patients 1.

More information

Jo Abraham MD Division of Nephrology University of Utah

Jo Abraham MD Division of Nephrology University of Utah Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive

More information

Waldenstrom s Macroglobulinemia

Waldenstrom s Macroglobulinemia Waldenstrom s Macroglobulinemia : Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called a B-lymphocyte or B-cell,

More information

A.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)

A.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified) chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst

More information

SUPPLEMENTARY APPENDIX

SUPPLEMENTARY APPENDIX SUPPLEMENTARY APPENDIX The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network Niels W.C.J.

More information

Test Utilization: Chronic Lymphocytic Leukemia

Test Utilization: Chronic Lymphocytic Leukemia Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.

More information

Serum Free Light Chain Assay

Serum Free Light Chain Assay Serum Free Light Chain Assay This Infosheet explains what light chains are, what the Serum Free Light Chain Assay is, and why it is used in AL amyloidosis. In AL amyloidosis, abnormal plasma cells in the

More information

I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015

I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015 I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015 Larry Anderson, MD, PhD Plasma Cell Disorder and Stem Cell Transplant Specialist UT Southwestern Medical

More information

Smouldering Myeloma: to treat or not to treat?

Smouldering Myeloma: to treat or not to treat? Smouldering Myeloma: to treat or not to treat? Massimo Offidani Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona Definitions and epidemiology 3000-5000 new SMM/year in

More information